Pharis Mohideen

2.1k total citations
25 papers, 1.4k citations indexed

About

Pharis Mohideen is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Pharis Mohideen has authored 25 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Molecular Biology and 6 papers in Surgery. Recurrent topics in Pharis Mohideen's work include Diabetes Treatment and Management (6 papers), Menopause: Health Impacts and Treatments (5 papers) and Diabetes Management and Research (4 papers). Pharis Mohideen is often cited by papers focused on Diabetes Treatment and Management (6 papers), Menopause: Health Impacts and Treatments (5 papers) and Diabetes Management and Research (4 papers). Pharis Mohideen collaborates with scholars based in United States, United Kingdom and Switzerland. Pharis Mohideen's co-authors include Theodore P. Ciaraldi, Robert R. Henry, Sunder Mudaliar, Svetlana E. Nikoulina, Jacqueline Barona, Markus Niggli, Changyu Pan, Yiting Wang, James E. Foley and Wenying Yang and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Pharis Mohideen

23 papers receiving 1.3k citations

Peers

Countries citing papers authored by Pharis Mohideen

Since Specialization

Citations

This map shows the geographic impact of Pharis Mohideen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pharis Mohideen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pharis Mohideen more than expected).

Fields of papers citing papers by Pharis Mohideen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pharis Mohideen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pharis Mohideen. The network helps show where Pharis Mohideen may publish in the future.

Co-authorship network of co-authors of Pharis Mohideen

This figure shows the co-authorship network connecting the top 25 collaborators of Pharis Mohideen. A scholar is included among the top collaborators of Pharis Mohideen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pharis Mohideen. Pharis Mohideen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Barriers and Solutions to Optimal Food Allergy Prevention, Diagnostic, and Management Strategies 2025 ·The Journal of Allergy and Clinical Immunology In Practice ·Stephen A. Tilles, Daniel C. Adelman, Matthew Greenhawt, Anne Marie Irani, Jay R. Lieberman, Pharis Mohideen, (unknown), H. A. Sampson, Marcus Shaker, (unknown), Yamini V. Virkud, Aikaterini Anagnostou	0
2	A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma 2020 ·Investigational New Drugs ·David C. Smith, Matthias Kroiß, Electron Kebebew, Mouhammed Amir Habra, Rashmi Chugh, Bryan J. Schneider, Martin Faßnacht, Pegah Jafarinasabian, (unknown), Vivian Lin, Pharis Mohideen, Aung Naing	46
3	Neurokinin 3 Receptor Antagonism Rapidly Improves Vasomotor Symptoms With Sustained Duration of Action 2019 ·Obstetrical & Gynecological Survey ·Julia Prague, Rachel Roberts, Alexander Comninos, Sophie Clarke, Channa Jayasena, Pharis Mohideen, Vivian Lin, Theresa Stern, Nicholas Panay, Myra S. Hunter, Lorraine Webber, Waljit S. Dhillo	1
4	SAT-100 Trial-in-Progress: ZEPHYR, a Pivotal Phase 2b/3 Randomized, Placebo-Controlled Study of Livoletide, a Novel Unacylated Ghrelin Analog, for the Treatment of Hyperphagia and Food-Related Behaviors in Patients with Prader-Willi Syndrome 2019 ·Journal of the Endocrine Society ·Soraya Allas, Pharis Mohideen, Thomas Delale, Vivian Lin, (unknown), Michael Yeh, M. Tauber	1
5	Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action 2018 ·Menopause The Journal of The North American Menopause Society ·Julia Prague, Rachel Roberts, Alexander Comninos, Sophie Clarke, Channa Jayasena, Pharis Mohideen, Vivian Lin, Theresa Stern, Nicholas Panay, Myra S. Hunter, Lorraine Webber, Waljit S. Dhillo	48
6	Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial 2017 ·The Lancet ·Julia Prague, Rachel Roberts, Alexander Comninos, Sophie Clarke, Channa Jayasena, Zachary Nash, (unknown), Deborah Papadopoulou, Stephen R. Bloom, Pharis Mohideen, Nicholas Panay, Myra S. Hunter, Johannes D. Veldhuis, Lorraine Webber, Les Huson, Waljit S. Dhillo	133
7	ATR-101 phase 1 clinical study for adrenocortical carcinoma. 2015 ·Journal of Clinical Oncology ·Aung Naing, Siqing Fu, Mouhammed Amir Habra, Rashmi Chugh, Electron Kebebew, Jeffrey S. Russell, (unknown), Martin Faßnacht, Matthias Kroiß, Maria-Elisabeth Goebeler, (unknown), Adam J. Plaunt, Pharis Mohideen, (unknown), David C. Smith	5
8	Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study 2012 ·Endocrine ·Christoph Beglinger, Ke Hu, Ying Wang, (unknown), Christelle Darstein, Yanfeng Wang, Pharis Mohideen	15
9	Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study 2012 ·Endocrine Related Cancer ·Larry K. Kvols, Kjell E. Öberg, Thomas M. O’Dorisio, Pharis Mohideen, Wouter W. de Herder, Rudolf Arnold, Ke Hu, Yilong Zhang, Gareth Hughes, Lowell Anthony, Bertram Wiedenmann	152
10	Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial 2010 ·The Journal of Clinical Endocrinology & Metabolism ·Stephan Petersenn, Jochen Schopohl, Ariel Barkan, Pharis Mohideen, Annamaria Colao, Roger Abs, (unknown), (unknown), Ke Hu, Andrew J. Farrall, Шломо Мелмед, Beverly M. K. Biller, (unknown)	157
11	Efficacy, Safety and Pharmacokinetic Results from a Phase II Study of Pasireotide (SOM230) in the Treatment of Patients with Metastatic NETs Refractory or Resistant to Octreotide LAR 2010 ·Neuroendocrinology ·Larry K. Kvols, Bertram Wiedenmann, Kjell Öberg, Pharis Mohideen, Thomas M. O’Dorisio, WW de Herder, (unknown), R. Arnold, Lowell Anthony	5
12	Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial 2008 ·Diabetic Medicine ·Changyu Pan, Wenying Yang, Jacqueline Barona, Yiting Wang, Markus Niggli, Pharis Mohideen, (unknown), James E. Foley	144
13	Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy 2006 ·Diabetes Care ·David M. Kendall, Cindy J. Rubin, Pharis Mohideen, Jean-Marie Ledeine, René Belder, Jorge Luiz Gross, Paul Norwood, Michael O’Mahony, Kenneth Sall, (unknown), (unknown), Fred T. Fiedorek, Ralph A. DeFronzo	88
14	The Metabolic Effects of Troglitazone in Patients with Diabetes and End-Stage Renal Disease 2005 ·Endocrine ·Pharis Mohideen, (unknown), (unknown), (unknown), (unknown), Richard F. Arakaki	8
15	Metformin‐glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy 2005 ·Diabetes Obesity and Metabolism ·A. J. Garber, E. Klein, Simon Bruce, Serap Sankoh, Pharis Mohideen	62
16	Insulin and insulin-like growth factor-1 action on human skeletal muscle: Preferential effects of insulin-like growth factor-1 in type 2 diabetic subjects 2002 ·Metabolism ·Theodore P. Ciaraldi, Leslie Carter, (unknown), Pharis Mohideen, Sunder Mudaliar, Robert R. Henry	24
17	Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study 2002 ·Clinical Therapeutics ·George Dailey, Pharis Mohideen, Fred T. Fiedorek	12
18	Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation 2001 ·Clinical Therapeutics ·Sunder Mudaliar, Pharis Mohideen, Sunita Baxi, M. Joyce, Debra Armstrong, Poul Strange, Robert R. Henry	3
19	Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. 2000 ·Diabetes ·Svetlana E. Nikoulina, Theodore P. Ciaraldi, Sunder Mudaliar, Pharis Mohideen, (unknown), Robert R. Henry	297
20	One hour in 1 ATA oxygen enhances rat alveolar macrophage chemiluminescence and fungal cytotoxicity 1991 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Richard M. Smith, Pharis Mohideen	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact